To read the full story, subscribe or sign in.

Sunovion Pharmaceuticals sees pivotal win with Cynapsus-sourced PD candidate

Jan. 31, 2018

Sunovion Pharmaceuticals Inc.'s $635 million buy of Cynapsus Therapeutics Inc. gained new validation with the success of a pivotal phase III trial testing the object of the deal, a sublingual version of the antiparkinsonian drug apomorphine.

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2026.

Depression concept with human, broken brain and heavy rain

CROI 2026 highlights depression and cognitive vulnerability in HIV

BioWorld

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 3, 2026

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

University of Southern California reports new MAPT aggregation inhibitors

BioWorld Science

The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...